375217
2-氯-4,6-二甲氧基-1,3,5-三嗪
97%
别名:
2,4-二甲氧基-6-氯-1,3,5-三嗪, 2,4-二甲氧基-6-氯-s-三嗪, 2-氯-4,6-二甲氧基-1,3,5-三嗪, 2-氯-4,6-二甲氧基-s-三嗪, 4,6-二甲氧基-2-氯-s-三嗪, 6-氯-2,4-二甲氧基-s-三嗪, CDMT, 氯二甲氧基三嗪
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C5H6ClN3O2
化学文摘社编号:
分子量:
175.57
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
221-541-0
Beilstein/REAXYS Number:
148988
MDL number:
产品名称
2-氯-4,6-二甲氧基-1,3,5-三嗪, 97%
InChI key
GPIQOFWTZXXOOV-UHFFFAOYSA-N
InChI
1S/C5H6ClN3O2/c1-10-4-7-3(6)8-5(9-4)11-2/h1-2H3
SMILES string
COc1nc(Cl)nc(OC)n1
assay
97%
form
solid
mp
71-74 °C (lit.)
functional group
chloro
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
2-氯-4,6-二甲氧基-1,3,5-三嗪可用于以下研究：
- 亲和标记的模块化方法 (MoAL) 对链霉亲和素的特异性标记。
- 通过与 2-羟基-4,6-二甲氧基-1,3,5-三嗪-2-基）醚反应制备双（4,6-二甲氧基-1,3,5-三嗪-2-基）醚。
- 通过与多种叔胺反应制备 2-（4,6-二甲氧基-1,3,5-三嗪基）三烷基铵盐。
- 在四氢呋喃中与 N -甲基吗啉偶联合成 4-（4,6-二甲氧基-1,3,5-三嗪-2-基）-4-甲基吗啉氯化物。
一种稳定并且具高反应性的肽偶联剂。
General description
2-氯-4,6-二甲氧基-1,3,5-三嗪是一种稳定但高度活性的肽偶联剂。它被报道为多肽纯化的有效偶联试剂。已报道 2-氯-4,6-二甲氧基-1,3,5-三嗪的催化酰胺化反应。已报道制备多千克 2-氯-4,6-二甲氧基-1,3,5-三嗪的方法。
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 2 - Eye Dam. 1 - Skin Corr. 1B - Skin Sens. 1
存储类别
8A - Combustible corrosive hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Munetaka Kunishima et al.
Chemical & pharmaceutical bulletin, 61(8), 882-886 (2013-08-02)
Effect of the basic property of reactants (tertiary amine catalysts, a substrate amine, and acid neutralizers) on catalytic dehydrocondensation between a carboxylic acid and an amine by using 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) was studied. The reaction yield was affected by the acid-base
2-Chloro-4, 6-dimethoxy-1, 3, 5-triazine. A new coupling reagent for peptide synthesis.
Kaminski ZJ.
Synthesis, 10, 917-920 (1987)
An improved procedure for the large scale preparation of 2-chloro-4, 6-dimethoxy-1, 3, 5-triazine.
Cronin JS, et al.
Synthetic Communications, 26(!8), 3491-3494 (1996)
E Johanna L Stéen et al.
ACS nano, 14(1), 568-584 (2019-12-11)
Tumor targeting using agents with slow pharmacokinetics represents a major challenge in nuclear imaging and targeted radionuclide therapy as they most often result in low imaging contrast and high radiation dose to healthy tissue. To address this challenge, we developed
Synthesis, 917-917 (1987)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持